Cargando…

Does Weight Impact Anidulafungin Pharmacokinetics?

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m(2)). Anidulafungin exposure was on average 32.5 % lower compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lempers, Vincent J., van Rongen, Anne, van Dongen, Eric P., van Ramshorst, Bert, Burger, David M., Aarnoutse, Rob E., Knibbe, Catherijne A., Brüggemann, Roger J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021753/ https://www.ncbi.nlm.nih.gov/pubmed/27142114 http://dx.doi.org/10.1007/s40262-016-0401-8

Ejemplares similares

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015)

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
por: Brill, Margreke J. E., et al.
Publicado: (2014)

Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
por: de Hoogd, Sjoerd, et al.
Publicado: (2017)

Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function
por: Smit, Cornelis, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
por: van Rongen, Anne, et al.
Publicado: (2017)

The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
por: Goulooze, Sebastiaan C., et al.
Publicado: (2018)

Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
por: van Rongen, Anne, et al.
Publicado: (2016)

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals
por: Smit, Cornelis, et al.
Publicado: (2020)

Pharmacokinetics of anidulafungin during albumin dialysis
por: Aguilar, Gerardo, et al.
Publicado: (2014)

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study
por: Smit, Cornelis, et al.
Publicado: (2019)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients
por: Smit, Cornelis, et al.
Publicado: (2019)

Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study
por: van Rhee, Koen P., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation
por: Aguilar, Gerardo, et al.
Publicado: (2016)

Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
por: Smit, Cornelis, et al.
Publicado: (2021)

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial
por: van Rongen, Anne, et al.
Publicado: (2018)

Implications for IV posaconazole dosing in the era of obesity
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children
por: Hartman, Stan J. F., et al.
Publicado: (2022)

An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children
por: Diepstraten, J, et al.
Publicado: (2013)

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates
por: Buil, J B, et al.
Publicado: (2020)

Pharmacokinetics, safety and tolerability of the novel β‐hCG derived immunomodulatory compound, EA‐230
por: van Groenendael, Roger, et al.
Publicado: (2019)

Fundament and Prerequisites for the Application of an Antifungal TDM Service
por: Brüggemann, Roger J. M., et al.
Publicado: (2015)

Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study
por: Hartman, Stan J. F., et al.
Publicado: (2021)

Paracetamol pharmacokinetics and metabolism in young women
por: Allegaert, Karel, et al.
Publicado: (2015)

Remifentanil versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial
por: de Hoogd, Sjoerd, et al.
Publicado: (2014)

Anidulafungin in the treatment of invasive fungal infections
por: Sabol, Kathryn, et al.
Publicado: (2008)

Anidulafungin and its role in candida infections
por: Cappelletty, Diane M, et al.
Publicado: (2009)

Anidulafungin: Lack of efficacy: case report
Publicado: (2022)

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy
por: Kantae, Vasudev, et al.
Publicado: (2016)

Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II”
por: Völler, Swantje, et al.
Publicado: (2021)

METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents – study protocol of a randomized controlled study
por: van der Aa, Marloes P, et al.
Publicado: (2014)

Invasive Fungal Infections in Infants—Focus on Anidulafungin
por: Wilke, Michael H.
Publicado: (2013)

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
por: Auzinger, G, et al.
Publicado: (2013)

Anidulafungin/voriconazole: Lack of efficacy: case report
Publicado: (2022)

Anidulafungin/antibacterials: Failure of response: case report
Publicado: (2022)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3t4d6h32u2phlrts5vmaukmk2e